2016
DOI: 10.1016/j.ebiom.2016.08.023
|View full text |Cite
|
Sign up to set email alerts
|

How benign is sickle cell trait?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
23
0
2

Year Published

2016
2016
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 27 publications
(25 citation statements)
references
References 9 publications
(11 reference statements)
0
23
0
2
Order By: Relevance
“…As such, we believe that the malaria protective effect of HbAS is strongly analogous to that which might be seen with malaria-specific interventions, including an effective malaria vaccine. While it has been shown that under specific circumstances, HbAS can result in adverse consequences 15,16 , it has never been associated with benefit against any other diseases in a non-malaria-endemic environment 16,17 . Specifically, while it has been shown that the risk of invasive bacterial infections is significantly reduced in HbAS children 10,18 , this has only been observed in areas endemic for malaria 10 .…”
Section: Discussionmentioning
confidence: 99%
“…As such, we believe that the malaria protective effect of HbAS is strongly analogous to that which might be seen with malaria-specific interventions, including an effective malaria vaccine. While it has been shown that under specific circumstances, HbAS can result in adverse consequences 15,16 , it has never been associated with benefit against any other diseases in a non-malaria-endemic environment 16,17 . Specifically, while it has been shown that the risk of invasive bacterial infections is significantly reduced in HbAS children 10,18 , this has only been observed in areas endemic for malaria 10 .…”
Section: Discussionmentioning
confidence: 99%
“…carrier status for the HbS variant) has been associated in some studies with a risk of sickling symptoms in particular circumstances, for example during extreme physical exertion and/or increased altitude [ 10 , 11 ]. While uncertainty remains as to the nature, severity, and extent of the risk associated with carrier status for sickle cell disease [ 12 ], particularly for the general population of carriers [ 13 – 17 ], it bears relevance to a broader debate concerning the disclosure to families of carrier results incidentally identified by NBS [ 18 , 19 ]. Specifically, while most NBS programs have opted for disclosure of all carrier status results to families, some have argued that this may impose undue burden, requiring families to be informed of incidentally generated and clinically ambiguous findings when they may neither need nor prefer to know [ 20 ].…”
Section: Introductionmentioning
confidence: 99%
“…Before, it was considered as a benign condition with protection to malaria and no painful episodes. However, several complications have been described in the literature as case reports, including venous thromboembolism, renal involvement, and splenic infarcts [5]. There are less than 100 reported cases of splenic infarcts in SCT associated with high altitude exposition [6,7].…”
Section: Introductionmentioning
confidence: 99%